Clinical trials: Refractory Non-Hodgkin Lymphoma
Lymphoma
Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma
RATIONALE: Giving colony-stimulating factors, such as G-CSF, monoclonal antibodies, such as rituximab, and chemotherapy, such as cyclophosphamide, helps stem cells move from the patient's bone marrow to the blood so they can be…
- Trial name
- NCT00242996
- Testing
- filgrastim, rituximab, sargramostim
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Non-Hodgkin's Lymphoma
Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab
SUMMARY: This is a multi-center open label study to evaluate the safety and effectiveness of Treanda™ (also known as bendamustine HCl or SDX-105) in patients who have indolent Non-Hodgkin's lymphoma and have relapsed within a…
- Trial name
- NCT00139841
- Testing
- Bendamustine HCl
- Where
- 40 sites in United States, Canada and 1 more
- Volunteers
- 103 people
- Sponsor
- Cephalon
B Cell Lymphoma
Clinical Study of U01（ssCART-19） in Patients With B-Cell Lymphoma
This is a single-arm, open-label clinical study evaluating the efficacy and safety of U01 (ssCART-19) in patients with relapsed or refractory B-cell lymphoma.
- Trial name
- NCT07093073
- Testing
- ssCART-19
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Colorectal Cancer, Hematologic Malignancy
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
One of the ways that cancer grows and spreads is by avoiding the immune system.NK cells are immune cells that kill cancer cells, but are often malfunctioning in people with colorectal cancer and blood cancers.
- Conditions
- Colorectal Cancer, Hematologic Malignancy, Rectum Cancer, Acute Myeloid Leukemia
- Trial name
- NCT05400122
- Testing
- Vactosertib, Fludarabine Phosphate, Cyclophosphamide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- David Wald
B-Cell Lymphoma Stage I, Refractory
CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma
Evaluation the safety and efficacy of CD19/CD20 bispecific CAR-T cells in patients with relapsed/refractory B cell lymphoma
- Conditions
- B-Cell Lymphoma Stage I, Refractory, Relapsed
- Trial name
- NCT03881761
- Testing
- CD19/CD20 bispecific CAR-T cells
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Henan Cancer Hospital
Follicular Lymphoma
Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma
This study in patients with relapsed/refractory follicular lymphoma who have undergone at least 3 lines of therapy. Patients will receive abexinostat 80 mg (4 × 20 mg tablets) twice a day (BID) in a "one week on, one week off"…
- Trial name
- FORERUNNER (NCT03600441)
- Testing
- Abexinostat
- Where
- 15 sites in United States, France and 1 more
- Volunteers
- 139 people
- Sponsor
- Xynomic Pharmaceuticals, Inc.
B-Cell Lymphoma
Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma
Clofarabine is a new chemotherapy drug which was FDA approved for the treatment of acute lymphocytic leukemia in children. This study is being done to see if Clofarabine works in adult patients with B-cell types of lymphoma.
- Trial name
- NCT00338494
- Testing
- Clofarabine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Yale University
Follicular Lymphoma (FL)
Efficacy and Safety of TC011 in Relapsed or Refractory Follicular Lymphoma
This Phase II, multi-center, single-arm, open-label study evaluates the efficacy and safety of TC011, a CD19-targeted CAR-T cell therapy, in adult patients with relapsed or refractory follicular lymphoma (Grade 1, 2, or 3a).
- Trial name
- TC011_FL_201 (NCT07360288)
- Testing
- TC011 single-arm
- Volunteers
- 40 people
- Sponsor
- TICAROS Co., Ltd.
Non-Hodgkin's Lymphoma
Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma
This study investigates toxicity and efficacy of 2 x R-DHAP followed by High dose chemotherapy R-TEC and autologous stem cell transplantation in patients with relapsed or refractory aggressive Non- Hodgkins's Lymphoma.
- Trial name
- NCT00384553
- Testing
- Rituximab, DHAP, TEC
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- University of Magdeburg
Relapsed/Refractory B-cell Lymphomas, Diffuse Large B-Cell Lymphoma (DLBCL)
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
This study is designed as a long-term follow-up study of participants who have receive genetically modified autologous CLBR001 CAR-T cells
- Conditions
- Relapsed/Refractory B-cell Lymphomas, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Chronic Lymphocytic Leukemia (CLL)
- Trial name
- NCT04488354
- Testing
- CLBR001 and SWI019
- Where
- 8 sites in United States
- Volunteers
- 16 people
- Sponsor
- Calibr, a division of Scripps Research
Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia
Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies
This clinical trial is designed as a single-arm, open-label, single-center, investigator-initiated, early-phase study. Its primary objective is to evaluate the safety of LV009 Injection in subjects with relapsed/refractory…
- Trial name
- NCT07284927
- Testing
- LV009 Injection
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Diffuse Large B-Cell Lymphoma
JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
This phase Ib trial studies whether anti-CD19-chimeric antigen receptor (CAR) lentiviral vector-transduced autologous T cells (JCAR014) and durvalumab are safe in combination and can work together in treating patients with…
- Conditions
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
- Trial name
- NCT02706405
- Testing
- Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014, Cyclophosphamide, Durvalumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Fred Hutchinson Cancer Center
Diffuse Large B Cell Lymphoma
Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC Positive
To evaluate the efficacy and safety of selinexor combined with BEAM pretreatment regimen in ASCT of recurrent and refractory DLBCL patients with immunohistochemical positive for MYC
- Trial name
- NCT06652139
- Testing
- selinexor combined with BEAM regimen, BEAM regimen
- Volunteers
- 82 people
- Sponsor
- Ruijin Hospital
Cancer
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies
Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety in patients with cancer.
- Trial name
- NCT01611623
- Testing
- SNX-5422
- Volunteers
- 9 people
- Sponsor
- Esanex Inc.
Multiple Myeloma, NonHodgkin Lymphoma
A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma
The Phase 1 portion of this study will determine the safety of TAS4464 and the most appropriate dose for patients with Multiple Myeloma or Lymphoma.
- Trial name
- NCT02978235
- Testing
- TAS4464
- Where
- 7 sites in United States
- Volunteers
- 11 people
- Sponsor
- Taiho Oncology, Inc.
Lymphoma, Large Cell, Diffuse, Lymphoma, Mixed Cell, Diffuse
CT-011 MAb in DLBCL Patients Following ASCT
Autologous peripheral blood stem cell transplantation combined with high dose chemotherapy is the treatment of choice given to patients with diffuse large-B cell lymphoma (DLBCL) following relapse of the disease.
- Conditions
- Lymphoma, Large Cell, Diffuse, Lymphoma, Mixed Cell, Diffuse, Primary Mediastinal Large B-Cell Lymphoma
- Trial name
- NCT00532259
- Testing
- CT-011
- Where
- 27 sites in United States, India and 1 more
- Volunteers
- 72 people
- Sponsor
- CureTech Ltd
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications
RATIONALE: A personalized Internet-based program may help improve fatigue, depression, and quality of life in long-term survivors of stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00799461
- Testing
- internet-based intervention, questionnaire administration, psychosocial assessment and care
- Where
- United States
- Volunteers
- 1,337 people
- Sponsor
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma
Retrospective Analysis on Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Treated With Z-BEAM Plus ASCT
Evaluate if Y90 Ibritumomab Tiuxetan Radioimmunotherapy in addition to standard high dose chemotherapy followed by autologous stem cell transplant could improve prognosis in patients affected by relapsed/refractory aggressive non…
- Trial name
- NCT02992223
- Volunteers
- 58 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas
The purpose of this research study is to find the maximum tolerated dose of a drug called romidepsin when given with a treatment regimen called GemOxD.
- Conditions
- Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse
- Trial name
- NCT02181218
- Testing
- Romidepsin, Gemcitabine, Oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Washington University School of Medicine
B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma Refractory
Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies
The goal of this open, single-arm practical, phase II, clinical study is to evaluate the efficacy and safety of the mitoxantrone hydrochloride liposome injection-containing regimens in bridging therapies of CD19 CAR-T cells.
- Trial name
- NCT06220097
- Testing
- Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T Cells
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology